Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349003 | 0.82 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL8468255 | 0.82 | CYP2C19 (0.34) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL7626939 | 0.81 | CYP2C19 (0.36) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL11468671 | 0.78 | LMNA (0.39) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL4811675 | 0.78 | MAPT (0.41) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL1417675 | 0.78 | CYP4F2 (0.37) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL29168788 | 0.78 | SIRT2 (0.40) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL31369191 | 0.78 | CYP4F2 (0.36) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL14799327 | 0.78 | CYP2C19 (0.33) | CYP2C19CYP3A4TSHRMAPTCYP2C9 | |
| SCHEMBL28553004 | 0.77 | SIRT2 (0.43) | CYP2C19CYP3A4CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524978-B2 | 2-oxabicyclo[3.3.0]octane compounds, process for producing the same, optical resolver, method of separating diastereomer mixture, and method of optically resolving alcohol | ZEON CORPORATION (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524978-B2 | 2-oxabicyclo[3.3.0]octane compounds, process for producing the same, optical resolver, method of separating diastereomer mixture, and method of optically resolving alcohol | ZEON CORPORATION (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1719746-A1 | OPTICAL RESOLVER, PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMER, AND 1,5-SUBSTITUTED BICYCLO (3.3.0) -2-OXAOCTANE COMPOUND | ZEON CORPORATION (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060205960-A1 | 2-Oxabicyclo[3.3.0]octane compounds, process for producing the same, optical resolver, method of separating diastereomer mixture, and method of optically resolving alcohol | ZEON CORPORATION (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1535917-A1 | 2-OXABICYCLO 3.3.0 OCTANE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, OPTICAL RESOLVER, METHOD OF SEPARATING DIASTEREOMER MIXTURE, AND METHOD OF OPTICALLY RESOLVING ALCOHOL | Zeon Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ALDH1A2, OXER1, HCRTR1 | CYP2C19 632/4885CYP3A4 638/4885TSHR 3778/4885 |
| US-20060205960-A1 | 2-Oxabicyclo[3.3.0]octane compounds, process for producing the same, optical resolver, method of separating diastereomer mixture, and method of optically resolving alcohol | OXER1, OR10J3, ADH1A | CYP2C19 1222/4885CYP3A4 348/4885TSHR 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.